EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Clinicopathological and genomic analysis of SWI/SNF chromatin remodeling abnormalities with a focus on SMARCA4 in cancer of unknown primary

Yasutaka Tono, Koshi Sukeno, Akira Tsunoda, Mariko Okayama, Hiroki Oka, Hiroyasu Oda, Kanako Saito, Yoshiki Yamashita, Masayasu Taniguchi, Makoto Ikejiri, Satoshi Tamaru, Masaki Tanabe und 3 weitere

Journal of Cancer Research and Clinical Oncology · 2025

DOI: 10.1007/s00432-025-06293-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Yasutaka Tono und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mie University Hospital, 2-174, Tsu, 514- 8507, Mie, Japan. ytono@med.mie-u.ac.jp. Hauptthemen laut MEDLINE: DNA Helicases, Transcription Factors, Nuclear Proteins, Neoplasms, Unknown Primary. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EKIDEN FOR LIFE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The estimation of the primary site is crucial when considering chemotherapy regimens in cancer of unknown primary (CUP). The task is particularly challenging for poorly differentiated or undifferentiated carcinoma, or unknown histological tumors with unknown primary (U-CUP). Instead of site-specific chemotherapy, a biomarker-guided therapy using genomic testing is required to predict the efficacy of molecular-targeted agents and immune checkpoint inhibitors (ICI). We focused on inactivating the SWI/SNF complex, a chromatin regulatory complex. We investigated the clinical features of CUP with SWI/SNF chromatin remodeling abnormalities and examined whether SWI/SNF chromatin remodeling abnormalities are a predictive marker of ICI efficacy.

Methods

A multi-institutional observational study was conducted between January 2009 and March 2022. Immunostaining for SMARCA2, SMARCA4, and SMARCB1 was performed on 80 patients with CUP. Nextgeneration sequencing analysis was conducted on SMARCA4 , SMARCA2 , SMARCB1 , ARID1A , PBRM1 , ARID2 , and ARID1B , which are frequent SWI/SNF-associated genes, in 32 patients with CUP.

Results

Immunohistochemistry revealed that the loss of SMARCA4 protein was most frequent, occurring in 14 patients (17.5%). Among the 32 patients with CUP, SMARCA4 mutations were detected in 50% ( n = 16) of patients. In 6 cases with truncating mutations, immunostaining revealed protein loss. U-CUP cases were associated with loss of SMARCA4 protein. In SMARCA4-deficient patients, overall survival was prolonged in the ICI-containing regimen group ( p = 0.033).

Conclusion

This study demonstrated SWI/SNF chromatin remodeling abnormalities in CUP and the association between SMARCA4 deficiency and U-CUP. It suggests a potential strategy for selecting an ICI regimen for CUP, particularly U-CUP, with SMARCA4 deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA HelicasesTranscription FactorsNuclear ProteinsNeoplasms, Unknown PrimaryChromatin Assembly and DisassemblyBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultSMARCB1 ProteinAged, 80 and overChromosomal Proteins, Non-HistoneImmune Checkpoint InhibitorsDNA-Binding ProteinsGenomicsMutation

Stichwörter der Autor:innen

Cancer of unknown primaryChromatin remodelingSMARCA4SWI/SNF

Substanzen

SMARCA4 protein, humanDNA HelicasesTranscription FactorsNuclear ProteinsBiomarkers, TumorSMARCB1 ProteinSMARCA2 protein, humanSMARCB1 protein, humanChromosomal Proteins, Non-HistoneImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Mie University Hospital, 2-174, Tsu, 514- 8507, Mie, Japan. ytono@med.mie-u.ac.jp.
  • Department of Medical Oncology, Mie University Hospital, 2-174, Tsu, 514- 8507, Mie, Japan.
  • Department of Medical Oncology, Ise Red Cross Hospital, Mie, 516-8512, Ise, Japan.
  • Department of Clinical Laboratory, Mie University Hospital, Tsu, 514-8507, Japan.
  • Clinical Research Support Center, Mie University Hospital, Tsu, 514-8507, Japan.
  • Pathology Division, Mie University Hospital, Tsu, 514-8507, Mie, Japan.

Förderung

  • EKIDEN FOR LIFE

Zitieren

APA

Tono, Y., Sukeno, K., Tsunoda, A., Okayama, M., Oka, H., Oda, H., Saito, K., Yamashita, Y., Taniguchi, M., Ikejiri, M., Tamaru, S., Tanabe, M., Imai, H., Watanabe, M., & Mizuno, T. (2025). Clinicopathological and genomic analysis of SWI/SNF chromatin remodeling abnormalities with a focus on SMARCA4 in cancer of unknown primary. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06293-9

Vancouver

Tono Y, Sukeno K, Tsunoda A, Okayama M, Oka H, Oda H, et al. Clinicopathological and genomic analysis of SWI/SNF chromatin remodeling abnormalities with a focus on SMARCA4 in cancer of unknown primary. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06293-9

BibTeX
@article{Tono2025,
  author = {Tono, Yasutaka and Sukeno, Koshi and Tsunoda, Akira and Okayama, Mariko and Oka, Hiroki and Oda, Hiroyasu and Saito, Kanako and Yamashita, Yoshiki and Taniguchi, Masayasu and Ikejiri, Makoto and Tamaru, Satoshi and Tanabe, Masaki and Imai, Hiroshi and Watanabe, Masatoshi and Mizuno, Toshiro},
  title = {Clinicopathological and genomic analysis of SWI/SNF chromatin remodeling abnormalities with a focus on SMARCA4 in cancer of unknown primary},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06293-9}
}
Kostenlos starten →